A226950 Stock Overview
Focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OliX Pharmaceuticals, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,430.00 |
| 52 Week High | ₩25,950.00 |
| 52 Week Low | ₩12,900.00 |
| Beta | 0.78 |
| 1 Month Change | -11.64% |
| 3 Month Change | -18.26% |
| 1 Year Change | -26.61% |
| 3 Year Change | -67.16% |
| 5 Year Change | -47.33% |
| Change since IPO | -59.05% |
Recent News & Updates
Shareholder Returns
| A226950 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.9% | -3.1% | 1.1% |
| 1Y | -26.6% | 12.6% | 3.7% |
Return vs Industry: A226950 underperformed the KR Biotechs industry which returned 13.8% over the past year.
Return vs Market: A226950 underperformed the KR Market which returned 4.4% over the past year.
Price Volatility
| A226950 volatility | |
|---|---|
| A226950 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A226950's share price has been volatile over the past 3 months.
Volatility Over Time: A226950's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 73 | Dong-Ki Lee | www.olixpharma.com |
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.
OliX Pharmaceuticals, Inc Fundamentals Summary
| A226950 fundamental statistics | |
|---|---|
| Market cap | ₩222.84b |
| Earnings (TTM) | -₩19.00b |
| Revenue (TTM) | ₩15.58b |
14.3x
P/S Ratio-11.7x
P/E RatioIs A226950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A226950 income statement (TTM) | |
|---|---|
| Revenue | ₩15.58b |
| Cost of Revenue | ₩179.23m |
| Gross Profit | ₩15.40b |
| Other Expenses | ₩34.40b |
| Earnings | -₩19.00b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15k |
| Gross Margin | 98.85% |
| Net Profit Margin | -122.00% |
| Debt/Equity Ratio | 116.1% |
How did A226950 perform over the long term?
See historical performance and comparison